- Home
- LSBK vs LUNG Comparison
LSBK vs LUNG Comparison
Compare LSBK & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- LUNG
- Stock Information
- Founded
- LSBK 1891
- LUNG 1995
- Country
- LSBK United States
- LUNG United States
- Employees
- LSBK N/A
- LUNG N/A
- Industry
- LSBK Savings Institutions
- LUNG Industrial Specialties
- Sector
- LSBK Finance
- LUNG Health Care
- Exchange
- LSBK Nasdaq
- LUNG Nasdaq
- Market Cap
- LSBK 90.0M
- LUNG 106.3M
- IPO Year
- LSBK 2006
- LUNG 2020
- Fundamental
- Price
- LSBK $12.15
- LUNG $3.34
- Analyst Decision
- LSBK
- LUNG Buy
- Analyst Count
- LSBK 0
- LUNG 6
- Target Price
- LSBK N/A
- LUNG $11.53
- AVG Volume (30 Days)
- LSBK 220.7K
- LUNG 420.0K
- Earning Date
- LSBK 07-23-2025
- LUNG 07-30-2025
- Dividend Yield
- LSBK 4.44%
- LUNG N/A
- EPS Growth
- LSBK 40.80
- LUNG N/A
- EPS
- LSBK 1.06
- LUNG N/A
- Revenue
- LSBK $26,488,000.00
- LUNG $87,473,000.00
- Revenue This Year
- LSBK N/A
- LUNG $18.02
- Revenue Next Year
- LSBK N/A
- LUNG $18.17
- P/E Ratio
- LSBK $11.51
- LUNG N/A
- Revenue Growth
- LSBK 1.75
- LUNG 19.84
- 52 Week Low
- LSBK $11.50
- LUNG $2.50
- 52 Week High
- LSBK $12.50
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- LSBK 62.69
- LUNG 57.32
- Support Level
- LSBK $11.50
- LUNG $2.99
- Resistance Level
- LSBK $12.38
- LUNG $3.88
- Average True Range (ATR)
- LSBK 0.25
- LUNG 0.34
- MACD
- LSBK 0.03
- LUNG 0.10
- Stochastic Oscillator
- LSBK 72.21
- LUNG 58.46
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.